An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275)
compared with placebo in participants with moderate to severe plaque type psoriasis.